Selected article for: "mg kg daily dose and MG11 administration"

Author: Shen, Zu T.; Sigalov, Alexander B.
Title: SARS Coronavirus Fusion Peptide-Derived Sequence Suppresses Collagen-Induced Arthritis in DBA/1J Mice
  • Document date: 2016_6_28
  • ID: 10wcqgaq_8
    Snippet: Previously, we reported that incorporation of another immunomodulatory peptide, GF9, that employs the SCHOOL mechanisms of action and targets triggering receptor expressed on myeloid cells 1 (TREM-1), into synthetic HDL-like nanoparticles of spherical shape (sHDL) significantly reduces the effective therapeutic dosage of GF9 in animal models of sepsis, lung cancer, and RA 33, 34 . To evaluate whether incorporation of MG11 into sHDL may have a sim.....
    Document: Previously, we reported that incorporation of another immunomodulatory peptide, GF9, that employs the SCHOOL mechanisms of action and targets triggering receptor expressed on myeloid cells 1 (TREM-1), into synthetic HDL-like nanoparticles of spherical shape (sHDL) significantly reduces the effective therapeutic dosage of GF9 in animal models of sepsis, lung cancer, and RA 33, 34 . To evaluate whether incorporation of MG11 into sHDL may have a similar effect, sHDL-bound MG11 was i.p. administered daily at a dose of 2.5 mg/kg MG11. Despite a 10-fold decrease in administration dose of MG11, the arthritis inhibitory effect observed for 2.5 mg/kg/day MG11-HDL was comparable to that observed for 25 mg/kg/day peptide in free form (Fig. 2a) . Although the underlying molecular mechanisms of this phenomenon are not completely understood and need to be further investigated, one can suggest that this results from the prolonged circulatory half-life of sHDL-bound MG11: while the in vivo peptide half-life is short, typically a few minutes 35 , sHDL are characterized by much longer half-lives up to 3-5 days 36 .

    Search related documents:
    Co phrase search for related documents
    • administration dose and half life: 1, 2, 3, 4, 5, 6, 7
    • administration dose and inhibitory effect: 1, 2, 3, 4, 5
    • administration dose and kg day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • administration dose and mg kg day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • administration dose and mg kg MG11 dose: 1
    • administration dose and MG11 administration dose: 1
    • animal model and half life: 1, 2, 3, 4
    • animal model and inhibitory effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • animal model and kg day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • animal model and lung cancer: 1, 2, 3
    • animal model and mg kg day: 1, 2, 3, 4, 5, 6, 7
    • free form and immunomodulatory peptide: 1
    • free form and inhibitory effect: 1, 2, 3, 4, 5
    • free form and kg day: 1
    • free form and mg kg day: 1
    • free form and mg kg MG11 dose: 1
    • half life and lung cancer: 1, 2, 3
    • half life and mg kg day: 1, 2, 3, 4, 5, 6, 7
    • half life and mg kg MG11 dose: 1